We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Simulations Demonstrate Neutron-Stimulated Emission CT and Gamma-Stimulated Emission CT to Be Safe

By MedImaging International staff writers
Posted on 16 Jun 2014
Print article
Image: Simulated three-dimensional (3D) dose measurements of the breast showing the dose imparted to the whole body. The dose is shown on a red and yellow color map, where yellow shows maximum dose (Photo courtesy of Duke Medicine).
Image: Simulated three-dimensional (3D) dose measurements of the breast showing the dose imparted to the whole body. The dose is shown on a red and yellow color map, where yellow shows maximum dose (Photo courtesy of Duke Medicine).
Image: Simulated 3D dose measurements of the abdomen/liver showing the dose imparted to the whole body. The dose is shown on a red and yellow color map, where yellow shows maximum dose (Photo courtesy of Duke Medicine).
Image: Simulated 3D dose measurements of the abdomen/liver showing the dose imparted to the whole body. The dose is shown on a red and yellow color map, where yellow shows maximum dose (Photo courtesy of Duke Medicine).
Gamma and neutron imaging offer possible enhancements over existing imaging techniques such as X-ray or computed tomography (CT), but their safety has not yet been fully determined. Using computer simulations, imaging the breast and liver with gamma or neutron radiation was found to be safe, delivering levels of radiation comparable with conventional medical imaging, according to researchers.

The findings, published in the June 2014 issue of the journal Medical Physics, will help researchers to move evaluation of gamma and neutron imaging into animals and later humans. Standard medical imaging tools, including X-ray, ultrasound, CT, and magnetic resonance imaging (MRI), identify disease by finding the anatomy, or shape and size, of the abnormality. When applying these applications to screen for cancer, a tumor must be large enough to be detected, and if found, a surgical biopsy is typically needed to determine if it is benign or malignant.

Duke University (Durham, NC, USA) researchers are working to develop imaging technologies to detect disease in its earliest stages, much before the tumors grow large enough to be detected using traditional approaches. Two imaging techniques they are researching are neutron-stimulated emission CT and gamma-stimulated emission CT.

Research has shown that many tumors have an out-of-balance concentration of trace-level elements naturally found in the body, such as rubidium and aluminum. These elements stray from their normal concentration levels at the earliest stages of tumor growth, potentially providing an early indication of disease.

The neutron and gamma imaging modalities measure the concentrations of elements in the body, determining molecular characteristics without the need for a biopsy or injection of contrast media. The goal is for these tests to be able to distinguish between benign and malignant lesions, as well as healthy tissue. “Gamma and neutron imaging may eventually be able to help us to detect cancer earlier without having to perform an invasive biopsy,” said Anuj Kapadia, PhD, assistant professor of radiology at Duke University School of Medicine and the study’s senior author.

Gamma and neutron imaging may also have applications for patients undergoing cancer treatment. Patients currently wait weeks or months to see if their cancer is responding to a particular treatment and shrinking in size, but gamma and neutron imaging may be able to tell if a treatment is working earlier by detecting molecular changes directly within the tumor.

While improved diagnostic tests would provide clinicians with useful tools, one ongoing question is the safety of gamma, and in particular, neutron radiation. Upon entering the body, neutrons scatter considerably, with the possibility of reaching several vital organs. Therefore, researchers have been apprehensive about how much radiation is absorbed in the targeted organ versus surrounding tissue. For instance, in a breast scan, the researchers need to know how much radiation is delivered unnecessarily to the heart or lungs.

Using detailed computer simulations, Dr. Kapadia and his colleagues estimated the radiation dose delivered to the liver and breast using neutron and gamma imaging. They found that the majority of radiation was delivered to organs directly within the radiation beam, and a much lower dose was absorbed by tissue outside of the radiation beam.

In simulated breast scans, the radiation was almost entirely limited to the area of the breast being scanned. The dose to the breast accounted for 96% of the radiation in neutron scans and 99 percent in gamma scans. The heart and lungs received less than 1% of the radiation dose.

When imaging the liver in simulation, the neutron scan imparted the highest radiation dose to the liver, while in the gamma scan, the stomach wall absorbed the greatest amount of radiation because of its location in the direct path of the beam. Further research is needed to decrease and better target gamma radiation doses in liver scans, according to the investigators. “The results show that despite the use of a highly scattering particle such as a neutron, the dose from neutron imaging is on par with other clinical imaging techniques such as X-ray CT,” Dr. Kapadia concluded. “Neutron and gamma radiation may become viable imaging alternatives if further testing proves them to be safe and effective.”

The researchers will use these data to move their studies into animals, and later, human trials.

Related Links:

Duke University


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Ultrasound Needle Guide
Ultra-Pro II
Compact C-Arm with FPD
Arcovis DRF-C R21
New
Breast Imaging Workstation
SecurView

Print article
Radcal

Channels

MRI

view channel
Image: PET/MRI can accurately classify prostate cancer patients (Photo courtesy of 123RF)

PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients

The Prostate Imaging Reporting and Data System (PI-RADS) is a five-point scale to assess potential prostate cancer in MR images. PI-RADS category 3 which offers an unclear suggestion of clinically significant... Read more

General/Advanced Imaging

view channel
Image: The Tyche machine-learning model could help capture crucial information. (Photo courtesy of 123RF)

New AI Method Captures Uncertainty in Medical Images

In the field of biomedicine, segmentation is the process of annotating pixels from an important structure in medical images, such as organs or cells. Artificial Intelligence (AI) models are utilized to... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.